Literature DB >> 35364122

Sex- and β-arrestin-dependent effects of kappa opioid receptor-mediated ethanol consumption.

Alexander R French1, Anna M Gutridge2, Jinling Yuan2, Q Hawk Royer2, Richard M van Rijn3.   

Abstract

The kappa opioid receptor is a known regulator of ethanol consumption, but the molecular mechanisms behind its actions have been underexplored. The scaffolding protein β-arrestin 2 has previously been implicated in driving ethanol consumption at the related delta opioid receptor and has also been suggested to be a driver behind other negative kappa opioid receptor mediated effects. Here, we used kappa opioid agonists with different efficacies for recruiting β-arrestin 2 and knockout animals to determine whether there is a role for β-arrestin 2 in the modulation of voluntary ethanol consumption by the kappa opioid receptor. We find that an agonist with low β-arrestin 2 efficacy more consistently lowers ethanol consumption than agonists with high efficacy for β-arrestin 2. However, knockdown of β-arrestin 2 amplifies the ethanol consumption-promoting effects of the arrestin-recruiting kappa agonists U50,488 and nalfurafine. We control for potentially confounding sedative effects at the kappa opioid receptor and find that β-arrestin 2 is not necessary for kappa opioid receptor-mediated sedation, and that sedation does not correlate with effects on ethanol consumption. Overall, the results suggest a complex relationship between agonist profile, sex, and kappa opioid receptor modulation of ethanol consumption, with little role for kappa opioid receptor-mediated sedation.
Copyright © 2022 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Biased signaling; HS666; Intermittent access; Locomotor; Nalfurafine; Two-bottle choice

Mesh:

Substances:

Year:  2022        PMID: 35364122      PMCID: PMC9064988          DOI: 10.1016/j.pbb.2022.173377

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.697


  43 in total

1.  mTORC1 pathway is involved in the kappa opioid receptor activation-induced increase in excessive alcohol drinking in mice.

Authors:  Yan Zhou; Yupu Liang; Mary Jeanne Kreek
Journal:  Pharmacol Biochem Behav       Date:  2020-05-26       Impact factor: 3.533

2.  Kappa opioid receptor activation of p38 MAPK is GRK3- and arrestin-dependent in neurons and astrocytes.

Authors:  Michael R Bruchas; Tara A Macey; Janet D Lowe; Charles Chavkin
Journal:  J Biol Chem       Date:  2006-04-28       Impact factor: 5.157

3.  The G protein-biased κ-opioid receptor agonist RB-64 is analgesic with a unique spectrum of activities in vivo.

Authors:  Kate L White; J Elliott Robinson; Hu Zhu; Jeffrey F DiBerto; Prabhakar R Polepally; Jordan K Zjawiony; David E Nichols; C J Malanga; Bryan L Roth
Journal:  J Pharmacol Exp Ther       Date:  2014-10-15       Impact factor: 4.030

Review 4.  Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research.

Authors:  Carol Kilkenny; William J Browne; Innes C Cuthill; Michael Emerson; Douglas G Altman
Journal:  PLoS Biol       Date:  2010-06-29       Impact factor: 8.029

5.  U50,488H-induced internalization of the human kappa opioid receptor involves a beta-arrestin- and dynamin-dependent mechanism. Kappa receptor internalization is not required for mitogen-activated protein kinase activation.

Authors:  J G Li; L Y Luo; J G Krupnick; J L Benovic; L Y Liu-Chen
Journal:  J Biol Chem       Date:  1999-04-23       Impact factor: 5.157

6.  Activation of the kappa opioid receptor in the dorsal raphe nucleus mediates the aversive effects of stress and reinstates drug seeking.

Authors:  Benjamin B Land; Michael R Bruchas; Selena Schattauer; William J Giardino; Megumi Aita; Daniel Messinger; Thomas S Hnasko; Richard D Palmiter; Charles Chavkin
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-28       Impact factor: 11.205

7.  Multi-dimensional analyses of behavior in mice treated with U-50,488H, a purported kappa (non-mu) opioid agonist.

Authors:  M Ukai; T Kameyama
Journal:  Brain Res       Date:  1985-07-01       Impact factor: 3.252

Review 8.  Advances in Achieving Opioid Analgesia Without Side Effects.

Authors:  Halina Machelska; Melih Ö Celik
Journal:  Front Pharmacol       Date:  2018-11-29       Impact factor: 5.810

Review 9.  Dynorphin/Kappa Opioid Receptor Signaling in Preclinical Models of Alcohol, Drug, and Food Addiction.

Authors:  Anushree Karkhanis; Katherine M Holleran; Sara R Jones
Journal:  Int Rev Neurobiol       Date:  2017-09-12       Impact factor: 3.230

10.  Responses to ethanol in C57BL/6 versus C57BL/6 × 129 hybrid mice.

Authors:  Jana P Lim; Mimi E Zou; Patricia H Janak; Robert O Messing
Journal:  Brain Behav       Date:  2012-01       Impact factor: 2.708

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.